comparative genomic analysis of primary versus metastasis in colorectal carcinomas
Post on 09-Jan-2016
41 Views
Preview:
DESCRIPTION
TRANSCRIPT
-
Comparative genomic analysis of primary versus metastasis in colorectal carcinomasEvi Vakiani, Manickam Janakiraman, Rileen Sinha, Ronglai Shen, Zhaong Zeng, Andrea Cercek, Nancy Kemeny, Adriana Heguy, Philip Paty, Timothy Chan, Len Saltz, Martin Weiser, David SolitHuman Oncogenesis and Pathogenesis Program &Departments of Pathology, Medicine, Surgery and BiostatisticsMemorial Sloan-Kettering Cancer Center, New York, NY
-
DisclosureThe authors have no financial conflicts of interest to disclose relevant to this study.
-
Metastatic colorectal carcinoma (CRC)A major cause of mortality
OConnell et al JNCI 2004; 96: 1420
-
Majority of CRCs arise from adenomasAdenomaPrimary invasive adenocarcinomaMetastasis
-
Targeted therapy of metastatic CRCThe EGFR pathway
-
AimsDefine the incidence of clinically relevant biological events in primary and metastatic CRC
Assess the concordance of such events between primary carcinomas and metastasis
Examine reasons for any observed discordances
-
Study Design & Methods736 frozen tumors from 613 patients39 adenomas, 406 primary carcinomas, 291 metastases84 pairs of matched primary tumors and metastases31 pairs of matched metastasesMatch confirmed by a fingerprinting assay
KRAS (exons 2,3,4)NRAS (exons 2,3)BRAF (exon 15) PIK3CA (exons 5, 7, 9, 20)TP53 (all coding exons)Study materialSequence analysis Sequenom MALDI-TOF mass spectrometry-based assay
Sanger
-
Study Design & MethodsIn matched pairs with discordant mutational profilesAnalysis of formalin-fixed paraffin embedded tissue (FFPE)Deep sequencing (454) (n=4)
DNA copy number analysis of matched primary tumors and metastasis N=25 pairsArray CGH (Agilent, 1M)
-
Clinical characteristics of study group
CharacteristicN=613Median age, years (range)62 (1788)Sex, % Male54.7 Female45.3Tumor Location, % Right Colon37.3 Left Colon43.7 Rectun18.9Stage at presentation, % I9.7 II18.1 III23.2 IV48.9
-
Incidence of RAS/BRAF mutationsN = 613RAS/BRAF wt, 48.4%G12C, 18G12A, 9G12D, 75G12R, 2G12S, 13G12V, 62G12N, 1G13C, 4G13D, 33Q61H/R/L/E, 12K117N, 3 A146T/V, 25NRAS G12D/13D, 6 NRAS Q61K/R/L, 12 BRAF V600E/G, 39 BRAF K601E, 1KRAS exon 2 mutations35.7%RAS mutations outside exon 29.4%BRAF mutations 6.5%
-
Incidence of PIK3CA mutations% PIK3CA mut casesp=0.00111.7%
Chart1
45
21
6
541
Column1
Sheet1
Column1
exon 9, 7.3%45
exon 20, 3.4%21
other, 1%6
wild type, 88.3%541
To resize chart data range, drag lower right corner of range.
-
Incidence of TP53 mutations% BRAF mut casesp=0.002
Chart1
247
366
Column1
Sheet1
Column1
TP53 mutant247
TP53 wt366
To resize chart data range, drag lower right corner of range.
- Incidence of mutations in primary tumors vs metastasisMutant (%)p=0.01p
- BRAF mutations in metastatic CRCp=0.01p
-
Concordance of mutational profile between matched primary tumor and metastasis
Frozen samples (N=84)GeneNumber of concordant cases%RAS/BRAF7892.8PIK3CA8196.4TP537690.5
Total7083.3
-
Concordance of mutational profile between matched primary tumor and metastasis
Frozen samplesAfter analysis of FFPE samplesGeneNumber of concordant cases%Number of concordant cases%RAS/BRAF7892.88297.6PIK3CA8196.48398.8TP537690.58095.2
Total7083.37690.5
-
Concordance of mutational profile between matched metastatic foci
Frozen samples (N=31)After analysis of FFPE samplesGeneNumber of concordant cases%Number of concordant cases%RAS/BRAF3096.731100PIK3CA3110031100TP532993.53096.7
Total2993.53096.7
-
Concordance of mutational profile between matched primary tumor and metastasisRAS/ BRAFPIK3CATP53
-
KRAS G12 (G35A)TP53 wtKRAS G12 (wt)TP53 R248QKRAS discordant cases20 PPrimary CRC in right colon20 LLiver metastasisClinical history of a primary sigmoid CRC GGA
-
Different KRAS mutational profiles in a case of multiple primary CRCCecal CRCRectal CRCLiver metsKRAS G12VKRAS A146TKRAS A146TTP53 wtTP53 R306*TP53 R306*
-
Concordance of mutational profile between matched primary tumor and metastasisRAS/ BRAFPIK3CATP53
-
Detection of a low frequency mutant allele in TP53 discordant casesKRAS G12V (G35T)TP53 R175H (G525A)TP 53 wtKRAS G12V (G35T)2.2% R175H79.5% R175HTP 53 (454)Primary CRCLiver metastasis
-
Concordance of mutational profile between matched primary tumor and metastasisRAS/ BRAFPIK3CATP53
-
DNA copy number analysis of matched pairs of primary CRC and metastasis (n=25)
-
SummaryKRAS/BRAF/PIK3CA mutations show a very high rate of concordance (>97%) between primary tumor and metastasis as well as between different metastatic foci
TP53 mutations show a high rate of concordance (>95%) between primary tumor and metastasis as well as between different metastatic foci
Reasons for observed discordances include cases of multiple primaries (KRAS), treatment effect (TP53) and presence of low level mutant alleles within primary tumor (TP53)
-
Conclusions
Genotyping for KRAS/BRAF/PIK3CA mutations can be performed using primary tumor DNA. In cases of multiple primaries, metastasis should be tested (in the absence of DNA from metastasis consider testing all primaries)
Genotyping for TP53 mutations is more accurate using DNA from metastatic foci.
-
David Solit Manickam JanakiramanAphrothiti HanrahanFeng XingYogi PersaudMoriah NissanGopa Iyer
Neal Rosen
Charles SawyersTim Chan
Adriana HeguyKety HubermanIgor DolgalevSabrena Thomas
Agnes Viale
Len SaltzNancy KemenyDiane ReidyAndrea Cercek
Phil PatyMarty WeiserZhaoshi Zeng
Mike DAngelicaYuman FongRonald DematteoPeter Allen
David KlimstraJinru ShiaLaura TangNora Katabi
Ronglai ShenRileen SinhaNick Socci
Cora MarianoPriscilla McNeilKatrina AllenAnas Idelbi
-
DNA copy number analysis in matched primary CRC and metastasis (n=25)29.8%39.1%Avg % aberration
Approximately 50,000 patients died of CRC in 2009*Mutually exclusive*Mutually exclusive*Mutually exclusive*
Primary % aberration 30%Liver mets % aberration 39% (p=0.13)
8 metachronous resection17 synchronous*
top related